PFS
FIG 2. · Panel PFS
Panel PFS 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Ruo-Xi Hong, Fei Xu, Wen Xia, Yue-E Teng, Qu-Chang Ouyang, Qiu-Fan Zheng, Zhong-Yu Yuan, Dong-Shao Chen, Kui-Kui Jiang, Ying Lin, Zhen Dai, Xin-Lan Liu, Qian-Jun Chen, Xin-Hong Wu, Yan-Xia Shi, Jia-Jia Huang, Xin An, Cong Xue, Xi-Wen Bi, Mei-Ting Chen, Hui Li, He-Rui Yao, Guo-Rong Zou, Heng Huang, Jing-Min Zhang, Shu-Sen Wang
J Clin Oncol 43(11) 1314-1324
PURPOSE: The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial. METHODS: Randomized clinical trials were conducted at 12 centers in China from August 22, 2017, to September 24, 2021, and the final follow-up date was August 25, 2023. Patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who had no previous systemic therapy in the metastatic setting were enrolled. Participants were 1:1 assigned to receive either metronomic capecitabine plus an aromatase inhibitor (AI) or AI alone. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), objective response rate, disease control rate (defined as disease controlled for ≥24 weeks), and safety. RESULTS: A total of 263 patients were randomly assigned, among which 254 patients formed the full analysis set. At the median follow-up time of 50.7 months, 203 PFS events occurred. The metronomic capecitabine plus AI arm exhibited a median PFS of 20.9 months compared with 11.9 months in the AI arm (hazard ratio [HR], 0.58 [95% CI, 0.43 to 0.76]). The median OS was not reached in the combination arm and was 45.1 months in the AI arm (HR, 0.58 [95% CI, 0.37 to 0.93]). The most common adverse events were palmar-plantar erythrodysesthesia and peripheral neuropathy; grade 3 events occurred in 15.1% of the patients receiving combination treatment. CONCLUSION: The MECCA trial demonstrated a significant improvement in PFS and OS with first-line metronomic capecitabine plus AI compared with AI alone in patients with hormone receptor-positive+/HER2-negative MBC. Both treatment arms exhibited tolerable safety profiles consistent with previous reports.
3 个 Figure · 3 个 KM 面板
FIG 2. Kaplan-Meier estimates of PFS in 254 patients with hormone receptor–positive, HER2-negative metastatic breast cancer. AI, aromatase inhibitor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PFS, progression-free survival.
FIG 2. · Panel PFS
Panel PFS 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 3. Kaplan-Meier estimates of OS in 254 patients with hormone receptor–positive, HER2-negative metastatic breast cancer. AI, aromatase inhibitor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; OS, overall survival.
FIG 3. · Panel OS
Panel OS 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A1. Kaplan-Meier estimates of PFS in patients with hormone receptor–positive, HER2-negative metastatic breast cancer excluding those who received AI in the adjuvant setting. AI, aromatase inhibitor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PFS, progression-free survival.
FIG A1. · Panel Kaplan-Meier_estimates_of_PFS
Panel Kaplan-Meier_estimates_of_PFS 是同一 FIG A1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。